These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24060868)

  • 41. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
    Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
    Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.
    Li YP; Ramirez S; Jensen SB; Purcell RH; Gottwein JM; Bukh J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19757-62. PubMed ID: 23151512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
    Vazquez C; Tan CY; Horner SM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
    Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
    Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
    White PW; Llinàs-Brunet M; Amad M; Bethell RC; Bolger G; Cordingley MG; Duan J; Garneau M; Lagacé L; Thibeault D; Kukolj G
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4611-8. PubMed ID: 20823284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
    Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
    J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
    Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.
    Gottwein JM; Scheel TK; Hoegh AM; Lademann JB; Eugen-Olsen J; Lisby G; Bukh J
    Gastroenterology; 2007 Nov; 133(5):1614-26. PubMed ID: 17983807
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies.
    Humes D; Ramirez S; Jensen TB; Li YP; Gottwein JM; Bukh J
    Virology; 2018 Sep; 522():177-192. PubMed ID: 30032031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HCV non-structural NS4A protein of genotype 3a induces mitochondria mediated death by activating Bax and the caspase cascade.
    Javed F; Manzoor S
    Microb Pathog; 2018 Nov; 124():346-355. PubMed ID: 30179714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.